Oncopeptides AB (publ) (ONCO.ST)
SEK 1.54
(1.18%)
SEK 1.54
(1.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -279.49 Million | -420.5 Million | -1.51 Billion | -1.29 Billion | -690.56 Million | -333.72 Million |
| Net Income | -249.11 Million | -349.35 Million | -1.42 Billion | -1.59 Billion | -739.39 Million | -419.3 Million |
| Depreciation & Amortization | 11.04 Million | 17.16 Million | 14.99 Million | 14.4 Million | 4.54 Million | 345 Thousand |
| Deferred income taxes | - | -19.14 Million | 34.19 Million | -68.2 Million | - | -149 Thousand |
| Stock-based compensation | 9.49 Million | 19.14 Million | -34.19 Million | 68.2 Million | 32.49 Million | 12.36 Million |
| Change in working capital | -54.62 Million | -109.23 Million | -38.08 Million | 142.27 Million | 58.69 Million | 40.84 Million |
| Other non-cash items | 24.24 Million | 20.91 Million | -72.38 Million | 138.09 Million | -46.9 Million | 32.16 Million |
| Investing Cash Flow | -116 Thousand | -2.5 Million | -339 Thousand | -20.12 Million | -2.62 Million | -907 Thousand |
| Investments in PPE | -116 Thousand | -2.5 Million | -339 Thousand | -17.18 Million | -2.62 Million | -369 Thousand |
| Acquisitions | - | - | - | -184 Thousand | - | - |
| Investment purchases | -1000.00 | - | - | -3.13 Million | - | -800 Thousand |
| Sales/Maturities of investments | - | - | - | 184 Thousand | - | 262 Thousand |
| Other Investing Activities | 1000.00 | - | - | 184 Thousand | -2.11 Million | 262 Thousand |
| Financing Cash Flow | 108.61 Million | 392.4 Million | 1.03 Billion | 1.32 Billion | 1.23 Billion | 304.89 Million |
| Debt repayment | -116.02 Million | -15.54 Million | -15.4 Million | -14.26 Million | -3.95 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -24 Thousand | -27.66 Million | -67.05 Million | -85.23 Million | -76.59 Million | -19.39 Million |
| Common Stock Issuance | - | 435.61 Million | 1.11 Billion | 1.42 Billion | 1.31 Billion | 324.28 Million |
| Other Financing Activities | 108.63 Million | 43.2 Million | 82.45 Million | 85.23 Million | 76.59 Million | -19.39 Million |
| Accounts receivables | -16.02 Million | 53.17 Million | 24.65 Million | -7.74 Million | -29.96 Million | -769 Thousand |
| Accounts payables | -13.19 Million | -22.88 Million | -104.91 Million | 55.14 Million | 55.71 Million | 9.58 Million |
| Inventory | -1.33 Million | -1.45 Million | -319 Thousand | -429 Thousand | - | - |
| Other working capital | -54.62 Million | -139.52 Million | 42.49 Million | 95.29 Million | 32.94 Million | 23.69 Million |
| Cash at beginning of period | 344.51 Million | 362.18 Million | 840.25 Million | 926.18 Million | 375.61 Million | 404.05 Million |
| Cash at end of period | 173.4 Million | 344.51 Million | 362.18 Million | 840.25 Million | 926.18 Million | 375.61 Million |
| Capital Expenditure | -116 Thousand | -2.5 Million | -339 Thousand | -17.18 Million | -2.62 Million | -369 Thousand |
| Effect of forex changes on cash | 1.61 Million | 12.94 Million | 4.63 Million | -92.75 Million | 7.47 Million | 1.3 Million |
| Net cash flow / Change in cash | -171.1 Million | -17.67 Million | -478.06 Million | -85.93 Million | 550.56 Million | -28.43 Million |
| Free Cash Flow | -279.6 Million | -423.01 Million | -1.51 Billion | -1.31 Billion | -693.19 Million | -334.09 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -73.24 Million | -67.7 Million | -249.11 Million | -81.21 Million | -37.29 Million | -62.43 Million |
| Depreciation & Amortization | - | - | 11.04 Million | 11.04 Million | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 9.49 Million | 3.59 Million | 3.1 Million | 4.6 Million |
| Change in working capital | 77.76 Million | -6.8 Million | -54.62 Million | 4.76 Million | -15.52 Million | -21.64 Million |
| Other non-cash items | 4.25 Million | 7.14 Million | 24.24 Million | 21.05 Million | -8.07 Million | 1.52 Million |
| Investing Cash Flow | - | - | -116 Thousand | -1000.00 | -115 Thousand | - |
| Investments in PPE | - | - | -116 Thousand | -116 Thousand | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -1000.00 | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 1000.00 | -1000.00 | -115 Thousand | - |
| Financing Cash Flow | 269.83 Million | -2 Million | 108.61 Million | -3.85 Million | -2.32 Million | 116.6 Million |
| Debt repayment | - | - | -116.02 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -24 Thousand | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 269.83 Million | -2 Million | 108.63 Million | -3.85 Million | -2.32 Million | 116.6 Million |
| Accounts receivables | - | - | -16.02 Million | -16.02 Million | - | - |
| Accounts payables | - | - | -13.19 Million | - | - | - |
| Inventory | - | - | -1.33 Million | -2.42 Million | - | - |
| Other working capital | 77.76 Million | -6.8 Million | -54.62 Million | 4.76 Million | -15.52 Million | -21.64 Million |
| Cash at beginning of period | 104.82 Million | 173.4 Million | 344.51 Million | 233.59 Million | 293.76 Million | 253.9 Million |
| Cash at end of period | 383.27 Million | 104.82 Million | 173.4 Million | 173.4 Million | 233.59 Million | 293.76 Million |
| Capital Expenditure | - | - | -116 Thousand | -116 Thousand | - | - |
| Effect of forex changes on cash | -160 Thousand | 785 Thousand | 1.61 Million | 791 Thousand | 61 Thousand | 568 Thousand |
| Net cash flow / Change in cash | 278.45 Million | -68.58 Million | -171.1 Million | -60.18 Million | -60.17 Million | 39.86 Million |
| Free Cash Flow | 8.77 Million | -67.36 Million | -279.6 Million | -55.51 Million | -57.79 Million | -77.3 Million |
PMREF
005420
SNTE
BCEKF
NTL
ALTOO